The Telmisartan Renoprotective Study from Incipient Nephropathy to Overt Nephropathy – Rationale, Study Design, Treatment Plan and Baseline Characteristics of the Incipient to Overt: Angiotensin II Receptor Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study

Author： Makino H   Haneda M   Babazono T   Moriya T   Ito S   Iwamoto Y   Kawamori R   Takeuchi M   Katayama S  

Publisher： Field House Publishing

ISSN： 0300-0605

Source： The Journal of International Medical Research, Vol.33, Iss.6, 2005-11, pp. : 677-686

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Effect of Ramipril Therapy on Cytokines and Parameters of Incipient Diabetic Nephropathy in Patients with Type 1 Diabetes Mellitus

By Janickova Zdarska D   Zavadova E   Kvapil M  

The Journal of International Medical Research, Vol. 35, Iss. 3, 2007-05 ,pp. : 374-383

Field House Publishing

Access to resources Recommend Favorite

A study on the relationship between homocysteine and diabetic nephropathy in rats

By ünlüçerçi Y.   Bekpinar S.   Gürdöl F.   Seferoğlu G.  

Pharmacological Research, Vol. 45, Iss. 3, 2002-03 ,pp. : 249-252

Academic Press

Access to resources Recommend Favorite

Telmisartan: a Different Angiotensin II Receptor Blocker Protecting a Different Population?

By Burnier M  

The Journal of International Medical Research, Vol. 37, Iss. 6, 2009-11 ,pp. : 1662-1679

Field House Publishing

Access to resources Recommend Favorite

Pharmacoeconomics of Angiotensin II Antagonists in Type 2 Diabetic Patients with Nephropathy: Implications for Decision Making

By Boersma Cornelis  

PharmacoEconomics, Vol. 24, Iss. 6, 2006-01 ,pp. : 523-535

Adis International

Access to resources Recommend Favorite

The Protective Effects of Angiotensin II Blockade with Olmesartan Medoxomil on Resistance Vessel Remodeling (The VIOS study): Rationale and Baseline Characteristics

By Smith Ronald D.  

American Journal of Cardiovascular Drugs, Vol. 6, Iss. 5, 2006-01 ,pp. : 335-342

Adis International

Access to resources Recommend Favorite